Pharmacogenomic testing for antidepressant selection can offer insights into how a patient’s body might tolerate certain treatment options and how effective the therapies may be in addressing their depression.
A recent trial (the GUIDED study) using GeneSight®, a specific brand of genetic test, reported improvement in depression symptoms among patients who had unsuccessfully tried other drugs in the past. GeneSight was developed by Myriad Genetics, which oversaw the trial.
Sagar V. Parikh, MD, FRCPC
John F. Greden Professor of Depression and Clinical Neuroscience
Professor of Psychiatry
Associate Director, University of Michigan Depression Center
Disclosures:
Consulting Fees: Assurex, Lundbeck, Sunovion, Takeda
Contracted Research: Assurex, Takeda
Ownership Interest: Mensante
